The Colony Stimulating Factors Market is expected to grow at a 7.90% CAGR during the forecast period for 2024-2031.
Colony stimulating factors (CSFs) are proteins that resemble hormones and encourage the development of immune cells that can fight infections. Human bodies manufacture CSFs from various cells, which can travel throughout the body and attach to cells with specific CSF receptors. CSFs can stimulate the synthesis of immune cells, which makes them useful as medications to boost the production of white blood cells. This could be a life-saving medication for patients whose immune systems have been destroyed by chemotherapy or specific immunodeficiency diseases. The primary factors propelling the growth of the global market for colony-stimulating factors are the rise in governmental funding for healthcare, rising cancer prevalence, and awareness of the availability of different cancer treatment alternatives. The growing need for prophylactic colony-stimulating factors is another significant reason for the market's expansion.
It is projected that improvements and advancements in genomics technology and healthcare will drive market expansion throughout the forecast period. Ongoing research and development of new cancer medicines and treatments for their side effects drive market growth. However, the market's growth is constrained by stringent government regulations for the approval of any new treatment options. The high cost is one of the critical obstacles limiting the CSF market from growing.
The Colony Stimulating Factors market is segmented on type, drug, application, dosage, route of administration, end-users and distribution channel. Based on type, the market is segmented into Macrophage–Colony-Stimulating Factor (M-CSF), Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF) and Granulocyte–Colony-Stimulating Factor (G-CSF). Based on the drug, the Colony Stimulating Factors are segmented into Pegfilgrastim, Tbo-filgrastim, Sargramostim and Filgrastim. Based on the application, the Colony Stimulating Factors are segmented into Aplastic Anemia, Bone Marrow Transplantation, Neutropenia, Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation and Peripheral Progenitor Cell Transplantations. Based on dosage, the Colony Stimulating Factors are segmented into Injection, Tablets, Capsules and Others. Based on route of administration, the market is segmented into Intravenous, Subcutaneous, Oral and Others. Based on end-user, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on distribution channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others.
Based on type, the market is segmented into Macrophage–Colony-Stimulating Factor (M-CSF), Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3), Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF) and Granulocyte–Colony-Stimulating Factor (G-CSF). The Granulocyte–Colony-Stimulating Factor (G-CSF) segment dominated the market. Following chemotherapy, the drug Granulocyte Colony-stimulating Factor (G-CSF) is used to treat cancer. Granulocyte-colony stimulating factor (G-CSF) is a glycoprotein that encourages the production of stem cells and granulocytes in the bone marrow and their release into the blood.
Based on the drug, the Colony Stimulating Factors are segmented into Pegfilgrastim, Tbo-filgrastim, Sargramostim and Filgrastim. The Pegfilgrastim segment dominated the market. Treating neutropenia (low white blood cells) brought on by cancer medications involves the injection of pegfilgrastim. It is a man-made version of a substance known as a colony-stimulating factor created naturally in your body. White blood cell production in the bone marrow is boosted by pegfilgrastim.
The North America Colony Stimulating Factors market is expected to register the highest market share in revenue in the near future. Some factors contributing to its highest share include the availability of well-established healthcare facilities and many individuals suffering from blood disorders. Furthermore, increased R&D initiatives to create new products will likely boost growth during the projection period. In addition, Asia Pacific is projected to grow rapidly in the global Colony Stimulating Factors market because of rising chronic illness occurrences, rising per capita income, greater access to healthcare facilities, treatment rates for GWCF medications such as granulocyte colony-stimulating (G-CSF) factor have increased. Additionally, growing public awareness of chronic diseases will fuel demand in this region.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 7.90% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, Application, Drug, Dosage, Route of Administration, Distribution Channel, End-User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Intas Pharmaceuticals Ltd., Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., GlaxoSmithKline plc, Biocon, Dr. Reddy's Laboratories Ltd., Amgen Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Stada Arzneimittel AG, Emcure Pharmaceuticals Limited., Celltrion, Inc, Biocad, Coherus BioSciences, Johnson & Johnson Private Limited, Eli Lilly and Company and Abbott. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
By Type-
By Drug-
By Application-
By Dosage-
By Route of Administration-
By End-Users
By Distribution Channel
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Colony Stimulating Factors Market Snapshot
Chapter 4. Global Colony Stimulating Factors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis
5.1. by Product Type & Market Share, 2023 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Product Type:
5.2.1. Macrophage–Colony-Stimulating Factor (M-CSF)
5.2.2. Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3)
5.2.3. Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)
5.2.4. Granulocyte–Colony-Stimulating Factor (G-CSF)
Chapter 6. Market Segmentation 2: by Drug Estimates & Trend Analysis
6.1. by Drug & Market Share, 2023 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Drug:
6.2.1. Pegfilgrastim
6.2.2. Tbo-filgrastim
6.2.3. Sargramostim
6.2.4. Filgrastim
Chapter 7. Market Segmentation 3: by Application Estimates & Trend Analysis
7.1. by Application & Market Share, 2023 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
7.2.1. Aplastic Anemia
7.2.2. Bone Marrow Transplantation
7.2.3. Neutropenia
7.2.4. Neutropenia Associated with Chemotherapy
7.2.5. Neutropenia Associated with Radiation
7.2.6. Peripheral Progenitor Cell Transplantations
Chapter 8. Market Segmentation 4: by Dosage Estimates & Trend Analysis
8.1. by Dosage & Market Share, 2023 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Dosage:
8.2.1. Injection
8.2.2. Tablets
8.2.3. Capsule
8.2.4. Others
Chapter 9. Market Segmentation 5: by Route of Administration Estimates & Trend Analysis
9.1. by Route of Administration & Market Share, 2023 & 2031
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Route of Administration:
9.2.1. Intravenous
9.2.2. Subcutaneous
9.2.3. Oral
9.2.4. Others
Chapter 10. Market Segmentation 6: by End-users Estimates & Trend Analysis
10.1. by End-users & Market Share, 2023 & 2031
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-users:
10.2.1. Hospitals
10.2.2. Specialty Clinics
10.2.3. Homecare
10.2.4. Others
Chapter 11. Colony Stimulating Factors Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Colony Stimulating Factors Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
11.1.2. North America Colony Stimulating Factors Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
11.1.3. North America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
11.1.4. North America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Dosage, 2024-2031
11.1.5. North America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
11.1.6. North America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by End-users, 2024-2031
11.1.7. North America Colony Stimulating Factors Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
11.2. Europe
11.2.1. Europe Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
11.2.2. Europe Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
11.2.3. Europe Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
11.2.4. Europe Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Dosage, 2024-2031
11.2.5. Europe Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
11.2.6. Europe Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by End-users, 2024-2031
11.2.7. Europe Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
11.3. Asia Pacific
11.3.1. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
11.3.2. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
11.3.3. Asia-Pacific Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
11.3.4. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Dosage, 2024-2031
11.3.5. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
11.3.6. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by End-users, 2024-2031
11.3.7. Asia Pacific Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
11.4. Latin America
11.4.1. Latin America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
11.4.2. Latin America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
11.4.3. Latin America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
11.4.4. Latin America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Dosage, 2024-2031
11.4.5. Latin America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
11.4.6. Latin America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by End-users, 2024-2031
11.4.7. Latin America Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
11.5. Middle East & Africa
11.5.1. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Product Type, 2024-2031
11.5.2. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Drug, 2024-2031
11.5.3. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
11.5.4. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Dosage, 2024-2031
11.5.5. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
11.5.6. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by End-users, 2024-2031
11.5.7. Middle East & Africa Colony Stimulating Factors Market revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Intas Pharmaceuticals Ltd.
12.2.2. Sanofi
12.2.3. Novartis AG
12.2.4. Teva Pharmaceutical Industries Ltd.
12.2.5. Pfizer, Inc.
12.2.6. GlaxoSmithKline plc
12.2.7. Biocon
12.2.8. Dr. Reddy's Laboratories Ltd.
12.2.9. Amgen Inc.
12.2.10. Merck KGaA
12.2.11. Takeda Pharmaceutical Company Limited
12.2.12. Thermo Fisher Scientific Inc.
12.2.13. Stada Arzneimittel AG
12.2.14. Emcure Pharmaceuticals Limited.
12.2.15. Celltrion, Inc
12.2.16. Biocad
12.2.17. Coherus BioSciences
12.2.18. Johnson & Johnson Private Limited
12.2.19. Eli Lilly and Company.
12.2.20. Abbott
12.2.21. Other Prominent Players